{"id":157445,"date":"2026-07-16T12:24:59","date_gmt":"2026-07-16T12:24:59","guid":{"rendered":"https:\/\/pabau.com\/?p=157445"},"modified":"2026-08-17T12:03:38","modified_gmt":"2026-08-17T12:03:38","slug":"hcpcs-code-j9332","status":"publish","type":"post","link":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/","title":{"rendered":"HCPCS Code J9332: Injection, efgartigimod alfa-fcab, 2 mg"},"content":{"rendered":"\n<script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"MedicalWebPage\",\"headline\":\"HCPCS Code J9332: Injection, efgartigimod alfa-fcab, 2 mg\",\"description\":\"Complete billing reference for HCPCS Code J9332 (efgartigimod alfa-fcab, 2 mg \/ Vyvgart). Covers Medicare fee schedule, ASP reimbursement, modifiers, ICD-10 crosswalk (G70.00, G70.01), and billing guidelines.\",\"url\":\"https:\/\/pabau.com\/procedure-codes\/hcpcs-code-j9332\/\",\"audience\":{\"@type\":\"MedicalAudience\",\"audienceType\":\"Clinician\"},\"reviewedBy\":{\"@type\":\"Person\",\"name\":\"Dr Vanja Kitanova\",\"jobTitle\":\"Medical Reviewer\",\"affiliation\":{\"@type\":\"Organization\",\"name\":\"Pabau\"},\"knowsAbout\":[\"Medical Coding\",\"Clinical Documentation\",\"Healthcare Billing\",\"Clinical Safety\"],\"sameAs\":\"https:\/\/pabau.com\/blog\/author\/vanja\/\"},\"datePublished\":\"2026-07-10\",\"dateModified\":\"2026-07-16\"}<\/script>\n\n\n        <div id=\"key_takeaways\">\n            <div class=\"header\">\n                                    <img decoding=\"async\" src=\"https:\/\/pabau.com\/wp-content\/uploads\/2025\/12\/Key-Takeaways-Icon.svg\" alt=\"Key Takeaways\" height=\"42\" width=\"42\">\n                                <h3>Key Takeaways<\/h3>\n            <\/div>\n            <div class=\"list\">\n                                                            <div class=\"item\">\n                            <div>\n                                <svg width=\"20\" height=\"27\" viewBox=\"0 0 20 27\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                                    <path\n                                        d=\"M18.6223 14.3857C19.1246 13.8975 19.1246 13.1045 18.6223 12.6162L12.1938 6.36621C11.6915 5.87793 10.8759 5.87793 10.3737 6.36621C9.87143 6.85449 9.87143 7.64746 10.3737 8.13574L14.6125 12.2529H2.28571C1.57455 12.2529 1 12.8115 1 13.5029C1 14.1943 1.57455 14.7529 2.28571 14.7529H14.6085L10.3777 18.8701C9.87545 19.3584 9.87545 20.1514 10.3777 20.6396C10.8799 21.1279 11.6955 21.1279 12.1978 20.6396L18.6263 14.3896L18.6223 14.3857Z\"\n                                        fill=\"#3D3D46\" \/>\n                                <\/svg>\n                            <\/div>\n                            <p>HCPCS Code J9332 describes injection of efgartigimod alfa-fcab, 2 mg (brand name Vyvgart), an FDA-approved IV treatment for generalized myasthenia gravis (gMG).<\/p>\n                        <\/div>\n                                                                                <div class=\"item\">\n                            <div>\n                                <svg width=\"20\" height=\"27\" viewBox=\"0 0 20 27\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                                    <path\n                                        d=\"M18.6223 14.3857C19.1246 13.8975 19.1246 13.1045 18.6223 12.6162L12.1938 6.36621C11.6915 5.87793 10.8759 5.87793 10.3737 6.36621C9.87143 6.85449 9.87143 7.64746 10.3737 8.13574L14.6125 12.2529H2.28571C1.57455 12.2529 1 12.8115 1 13.5029C1 14.1943 1.57455 14.7529 2.28571 14.7529H14.6085L10.3777 18.8701C9.87545 19.3584 9.87545 20.1514 10.3777 20.6396C10.8799 21.1279 11.6955 21.1279 12.1978 20.6396L18.6263 14.3896L18.6223 14.3857Z\"\n                                        fill=\"#3D3D46\" \/>\n                                <\/svg>\n                            <\/div>\n                            <p>Medicare Part B reimburses J9332 at ASP plus 6%, updated quarterly by CMS. Rates vary by billing setting (hospital outpatient vs physician office).<\/p>\n                        <\/div>\n                                                                                <div class=\"item\">\n                            <div>\n                                <svg width=\"20\" height=\"27\" viewBox=\"0 0 20 27\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                                    <path\n                                        d=\"M18.6223 14.3857C19.1246 13.8975 19.1246 13.1045 18.6223 12.6162L12.1938 6.36621C11.6915 5.87793 10.8759 5.87793 10.3737 6.36621C9.87143 6.85449 9.87143 7.64746 10.3737 8.13574L14.6125 12.2529H2.28571C1.57455 12.2529 1 12.8115 1 13.5029C1 14.1943 1.57455 14.7529 2.28571 14.7529H14.6085L10.3777 18.8701C9.87545 19.3584 9.87545 20.1514 10.3777 20.6396C10.8799 21.1279 11.6955 21.1279 12.1978 20.6396L18.6263 14.3896L18.6223 14.3857Z\"\n                                        fill=\"#3D3D46\" \/>\n                                <\/svg>\n                            <\/div>\n                            <p>Use modifier JW to report discarded drug waste and modifier JZ when there is zero waste. Conflating J9332 with J9334 (Vyvgart Hytrulo, subcutaneous) is a critical billing error.<\/p>\n                        <\/div>\n                                                                                <div class=\"item\">\n                            <div>\n                                <svg width=\"20\" height=\"27\" viewBox=\"0 0 20 27\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                                    <path\n                                        d=\"M18.6223 14.3857C19.1246 13.8975 19.1246 13.1045 18.6223 12.6162L12.1938 6.36621C11.6915 5.87793 10.8759 5.87793 10.3737 6.36621C9.87143 6.85449 9.87143 7.64746 10.3737 8.13574L14.6125 12.2529H2.28571C1.57455 12.2529 1 12.8115 1 13.5029C1 14.1943 1.57455 14.7529 2.28571 14.7529H14.6085L10.3777 18.8701C9.87545 19.3584 9.87545 20.1514 10.3777 20.6396C10.8799 21.1279 11.6955 21.1279 12.1978 20.6396L18.6263 14.3896L18.6223 14.3857Z\"\n                                        fill=\"#3D3D46\" \/>\n                                <\/svg>\n                            <\/div>\n                            <p>Pabau&#8217;s claims management software supports accurate HCPCS J-code tracking, modifier documentation, and billing workflow automation for infusion practices.<\/p>\n                        <\/div>\n                                                <\/div>\n        <\/div>\n    \n\n\n<p class=\"wp-block-paragraph\">HCPCS Code J9332 reports injection of efgartigimod alfa-fcab, 2 mg (brand name Vyvgart), administered intravenously. It applies exclusively to the IV formulation. The subcutaneous version, Vyvgart Hytrulo, carries a separate code, J9334, and conflating the two creates claim denials that are slow to correct.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This guide covers the code description, Medicare fee schedule methodology, applicable modifiers, ICD-10 diagnosis crosswalk, billing guidelines, and related codes for J9332.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">HCPCS Code J9332: quick reference<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The table below shows the canonical code data for J9332, drawn from the <a href=\"https:\/\/www.cms.gov\/medicare\/coding-billing\/healthcare-common-procedure-system\" target=\"_blank\" rel=\"nofollow noopener\">CMS HCPCS Level II coding system<\/a>. Billers should confirm effective dates annually, as CMS updates the HCPCS code file each January.<\/p>\n\n\n\n<table style=\"width:100%;border-collapse:separate;border-spacing:0;border-radius:12px;overflow:hidden;font-size:15px;line-height:1.5;margin:1.5em 0 2em;box-shadow:0 2px 12px rgba(0,0,0,0.08)\">\n<thead>\n<tr>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">Field<\/th>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">Detail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"border-bottom:1px solid #E8ECF0\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">HCPCS Code<\/td>\n<td style=\"padding:12px 16px;color:#374151\">J9332<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0;background:#F9FAFB\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Long Description<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Injection, efgartigimod alfa-fcab, 2 mg<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Short Description<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Inj efgartigimod 2mg<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0;background:#F9FAFB\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Brand Name<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Vyvgart (IV formulation)<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Code Category<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Chemotherapy \/ antineoplastic drugs (J9000-J9999)<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0;background:#F9FAFB\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Code Level<\/td>\n<td style=\"padding:12px 16px;color:#374151\">HCPCS Level II<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Effective Date<\/td>\n<td style=\"padding:12px 16px;color:#374151\">July 1, 2022<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0;background:#F9FAFB\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Unit of Service<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Per 2 mg of efgartigimod alfa-fcab administered<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Route of Administration<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Intravenous (IV infusion)<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0;background:#F9FAFB\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Primary Payer<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Medicare Part B (also commercial payers)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n<h2 class=\"wp-block-heading\">What is efgartigimod alfa-fcab (Vyvgart)?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Efgartigimod alfa-fcab is a human IgG1 antibody fragment developed by argenx to treat generalized myasthenia gravis (gMG). The FDA approved Vyvgart in December 2021, making it the first approved FcRn blocker for gMG. It works by reducing circulating IgG antibodies, including the pathogenic acetylcholine receptor antibodies responsible for the muscle weakness characteristic of gMG.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Billing teams encounter two distinct products from argenx, each with its own HCPCS code. J9332 covers the original IV formulation (Vyvgart), administered as a one-hour infusion. J9334 covers Vyvgart Hytrulo, the subcutaneous formulation that combines efgartigimod alfa with hyaluronidase-qvfc.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">These are not interchangeable codes. Submitting J9332 for a subcutaneous administration, or J9334 for an IV infusion, constitutes a billing error and typically results in a denial.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Approved indication:<\/strong> generalized myasthenia gravis (gMG) in adult patients, across all antibody serotypes (AChR-positive, MuSK-positive, LRP4-positive, and seronegative), following the FDA&#8217;s May 2026 label expansion<\/li><li><strong>Route of administration (J9332):<\/strong> intravenous infusion over approximately 1 hour<\/li><li><strong>Dosing cycle:<\/strong> 10 mg\/kg IV once weekly for 4 weeks; cycles repeat based on clinical response<\/li><li><strong>Manufacturer:<\/strong> argenx (publishes a dedicated billing and coding guide at vyvgarthcp.com)<\/li><li><strong>Subcutaneous variant:<\/strong> Vyvgart Hytrulo, billed separately under J9334, not J9332<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Medicare fee schedule and reimbursement rates for J9332<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Medicare Part B covers J9332 as a separately payable drug benefit under the ASP (Average Sales Price) methodology. CMS updates ASP-based payment rates every quarter, so the figures in the table below are representative and should always be confirmed against the current <a href=\"https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search\/overview\" target=\"_blank\" rel=\"nofollow noopener\">CMS Physician Fee Schedule lookup tool<\/a> or the quarterly ASP Drug Pricing File before billing.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The standard Medicare payment formula is ASP plus 6%. The 6% add-on covers the cost of acquiring and storing the drug. This formula applies in both the physician office and hospital outpatient settings, though the base ASP figure and cost-sharing structures differ between settings.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Payment by billing setting: hospital outpatient vs physician office<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Where a patient receives their infusion matters for reimbursement. Hospital outpatient departments (HOPDs) bill under the Outpatient Prospective Payment System (OPPS), which incorporates different fee schedule rates and cost-sharing rules compared to the physician office setting. The table below outlines the key differences.<\/p>\n\n\n\n<table style=\"width:100%;border-collapse:separate;border-spacing:0;border-radius:12px;overflow:hidden;font-size:15px;line-height:1.5;margin:1.5em 0 2em;box-shadow:0 2px 12px rgba(0,0,0,0.08)\">\n<thead>\n<tr>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">Feature<\/th>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">Physician Office<\/th>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">Hospital Outpatient (HOPD)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"border-bottom:1px solid #E8ECF0\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Payment system<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Medicare Physician Fee Schedule (MPFS)<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Outpatient Prospective Payment System (OPPS)<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0;background:#F9FAFB\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Drug payment formula<\/td>\n<td style=\"padding:12px 16px;color:#374151\">ASP + 6%<\/td>\n<td style=\"padding:12px 16px;color:#374151\">ASP + 6% (may differ under OPPS packaging rules)<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Claim form<\/td>\n<td style=\"padding:12px 16px;color:#374151\">CMS-1500 (professional)<\/td>\n<td style=\"padding:12px 16px;color:#374151\">UB-04 (institutional)<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0;background:#F9FAFB\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Patient cost-sharing<\/td>\n<td style=\"padding:12px 16px;color:#374151\">20% coinsurance after deductible<\/td>\n<td style=\"padding:12px 16px;color:#374151\">OPPS copayment applies (may be lower)<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Infusion administration code<\/td>\n<td style=\"padding:12px 16px;color:#374151\">CPT 96365 (initial), 96366 (additional hour)<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Billed per OPPS APC grouping<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0;background:#F9FAFB\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">Rate update frequency<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Quarterly (ASP file)<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Quarterly (ASP file)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n<p class=\"wp-block-paragraph\">Practices using claims management software that integrates fee schedule data can reduce the manual burden of tracking quarterly ASP updates. Reconciling rates against the quarterly CMS file is the most reliable way to avoid underbilling or overbilling on J9332 claims.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/cdn.pabau.com\/cdn\/attachments\/pulse\/content-engine\/billing_codes\/hcpcs-code-j9332\/automate-claims-through-healthcode.webp\" alt=\"Automate claims and billing with Pabau\"\/><figcaption class=\"wp-element-caption\"><em>Automate claims and billing with Pabau<\/em><\/figcaption><\/figure>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n\n\n<p class=\"wp-block-paragraph\">A <a href=\"https:\/\/pabau.com\/industry\/weight-loss-clinic-software\/\">weight loss clinic platform<\/a> keeps GLP-1 dosing, stock, and follow-ups aligned across the whole program.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Applicable modifiers for J9332<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Two modifiers are central to accurate J9332 billing: JW and JZ. CMS policy requires one of these on every single-dose vial drug claim. Omitting them entirely creates an edit that many Medicare Administrative Contractors (MACs) will reject.<\/p>\n\n\n\n<table style=\"width:100%;border-collapse:separate;border-spacing:0;border-radius:12px;overflow:hidden;font-size:15px;line-height:1.5;margin:1.5em 0 2em;box-shadow:0 2px 12px rgba(0,0,0,0.08)\">\n<thead>\n<tr>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">Modifier<\/th>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">Name<\/th>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">When to Use<\/th>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">Billing Behavior<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"border-bottom:1px solid #E8ECF0\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">JW<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Drug amount discarded<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Portion of vial content was not administered and discarded<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Report the administered dose on one line; discarded amount on a second line with JW modifier<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0;background:#F9FAFB\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">JZ<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Zero drug waste<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Full vial content was administered with no waste (e.g., dose matches vial size exactly)<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Report on the administered dose line; no second line required<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n<p class=\"wp-block-paragraph\">CMS introduced JZ modifier reporting on single-dose vial drugs as optional starting January 1, 2023, then made it mandatory from July 1, 2023. MACs began editing and rejecting claims that omitted the JW or JZ modifier from October 1, 2023 onward. The policy applies to J9332 because Vyvgart is supplied as a single-dose vial.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Verify the current requirements against the <a href=\"https:\/\/www.aapc.com\/codes\/hcpcs-codes-range\/\" target=\"_blank\" rel=\"nofollow noopener\">AAPC HCPCS code lookup<\/a> or the applicable MAC&#8217;s LCD for the most current guidance, as modifier policy can update independently of the annual HCPCS code file.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Beyond JW and JZ, commercial payers may require additional modifiers (such as modifier 59 for distinct procedural services, or payer-specific modifiers). Always check individual payer policies before submitting. Good EHR integration for billing workflows can flag modifier requirements automatically based on payer rules stored in the system.<\/p>\n\n\n        <div id=\"pro_tip\">\n            <div class=\"img\">\n                <svg width=\"42\" height=\"42\" viewBox=\"0 0 42 42\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path fill-rule=\"evenodd\" clip-rule=\"evenodd\"\n                        d=\"M12.6383 19.5238C12.6632 21.2071 12.8734 22.9926 12.0685 24.5523C11.0341 26.8917 8.45076 28.169 7.56292 30.5918C6.63082 33.1061 7.19505 36.185 9.31371 37.9786C10.929 39.5678 13.4183 39.9873 15.6061 39.5463C17.4592 39.073 19.1049 37.8388 19.9706 36.1608C20.781 34.7141 20.7866 32.9904 20.5293 31.3985C20.1006 29.3092 18.3775 27.8705 16.9807 26.362C14.8814 24.1005 14.6684 20.6854 15.595 17.8915C16.4331 15.4768 19.0026 14.2344 20.0425 11.9461C20.7202 10.6769 20.7506 9.20327 20.6068 7.81304C20.1864 5.40098 18.3139 3.23631 15.8716 2.56674C13.9742 2.03969 11.8224 2.30052 10.1739 3.37614C8.70522 4.34688 7.5878 5.86618 7.28356 7.58178C6.76081 9.82981 7.53525 12.2822 9.20307 13.9118C10.7658 15.4741 12.4806 17.2273 12.6383 19.5238Z\"\n                        fill=\"#2BADD4\" \/>\n                    <path fill-rule=\"evenodd\" clip-rule=\"evenodd\"\n                        d=\"M22.7048 19.8387C22.6822 22.3279 24.4507 24.6234 26.7493 25.4682C28.0531 25.961 29.4725 25.9183 30.7989 25.5487C32.0575 24.9955 33.301 24.2237 34.0069 23.0092C34.8384 21.5811 35.2982 19.8286 34.7832 18.2094C34.3611 16.2507 32.8739 14.6541 31.0275 13.9426C28.6736 12.9595 25.8073 13.7942 24.1719 15.7001C23.2022 16.8366 22.6143 18.3326 22.7048 19.8387Z\"\n                        fill=\"#2BADD4\" \/>\n                <\/svg>\n            <\/div>\n            <div class=\"text\">\n                <h3>Pro Tip<\/h3>\n                <p>Track every J9332 infusion with a two-line billing setup: line 1 for units administered, line 2 (JW) for units wasted. Document the actual mg administered and the mg wasted directly in the patient chart at the time of service. This creates the audit trail CMS requires without needing to reconstruct it later.<\/p>\n            <\/div>\n        <\/div>\n    \n\n\n<h2 class=\"wp-block-heading\">ICD-10 diagnosis codes used with J9332<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Linking J9332 to the correct ICD-10 diagnosis code is a medical necessity requirement. Medicare and most commercial payers will deny the claim if the diagnosis code submitted does not support the use of efgartigimod alfa-fcab.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The two primary codes are both myasthenia gravis codes within the G70 category, and the distinction between them matters. Neurologists coding other cranial nerve conditions alongside gMG may also reference G53 on our diagnostic code reference pages.<\/p>\n\n\n\n<table style=\"width:100%;border-collapse:separate;border-spacing:0;border-radius:12px;overflow:hidden;font-size:15px;line-height:1.5;margin:1.5em 0 2em;box-shadow:0 2px 12px rgba(0,0,0,0.08)\">\n<thead>\n<tr>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">ICD-10-CM Code<\/th>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">Description<\/th>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">Coding Guidance<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"border-bottom:1px solid #E8ECF0\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">G70.01<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Myasthenia gravis with (acute) exacerbation<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Use when patient presents with active exacerbation at time of infusion. Use only when documentation supports an active exacerbation at the encounter.<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0;background:#F9FAFB\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">G70.00<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Myasthenia gravis without (acute) exacerbation<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Use when patient is in maintenance treatment phase without active exacerbation. Confirm clinical documentation supports the absence of exacerbation.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n<p class=\"wp-block-paragraph\">For J9332 claims, the treating neurologist&#8217;s documentation should clearly state whether an exacerbation is present, the same specificity payers expect for other muscle disorder diagnoses. Payers may audit this distinction closely, particularly for high-cost biologics where medical necessity review is common.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Some payer Local Coverage Determinations (LCDs) may specify additional diagnosis codes required for coverage. Always check the applicable MAC&#8217;s LCD for gMG biologics before submitting, and verify coverage against the individual patient&#8217;s plan when billing commercial payers or Medicare Advantage.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">HCPCS Code J9332 billing guidelines<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Accurate J9332 billing requires matching the number of units billed to the exact dose administered. Because the code is defined per 2 mg, a standard 10 mg\/kg infusion will generate multiple units depending on patient weight.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Document the prescribed dose, the actual dose administered, and any waste in the patient record before submitting the claim. Good medical forms and documentation workflows reduce the risk of unit calculation errors at the time of billing.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Units of service calculation<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">J9332 is billed per 2 mg. To calculate the number of units, divide the total milligrams administered by 2. Round up to the nearest whole unit for any partial unit administered.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For example, a 70 kg patient receiving a 10 mg\/kg dose receives 700 mg total. That is 350 units of J9332 (700 mg divided by 2 mg per unit). Wasted drug is reported on a separate claim line with modifier JW.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Prior authorization and payer requirements<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Many payers require prior authorization for J9332 before the first infusion. Requirements differ significantly across payers and plan years. Medicare fee-for-service generally does not require prior authorization for separately payable Part B drugs, but Medicare Advantage plans and commercial payers often do. Revenue cycle compliance requirements for high-cost biologics typically include:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Confirmed diagnosis of gMG (antibody documentation may include AChR, MuSK, or LRP4 status, or note a seronegative result \u2014 a positive AChR test is no longer required for coverage)<\/li><li>Documentation of prior treatment failure or contraindication to first-line therapies (acetylcholinesterase inhibitors, corticosteroids)<\/li><li>Treating physician specialty and credentials (typically a board-certified neurologist)<\/li><li>Treatment plan specifying intended cycle count and response assessment timeline<\/li><li>Relevant lab results and functional assessment scores (e.g., MG-ADL scale) where required by payer policy<\/li><\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Use digital intake and prior authorization forms to capture and store the required documentation at the point of care. Keeping authorization numbers, expiration dates, and supporting clinical notes in a structured record reduces claim delays. Review documentation compliance requirements for medical offices to ensure your authorization workflow meets HIPAA standards for record retention.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/cdn.pabau.com\/cdn\/attachments\/pulse\/content-engine\/billing_codes\/hcpcs-code-j9332\/customizable-consent-and-intake-forms.webp\" alt=\"Customizable consent and intake forms\"\/><figcaption class=\"wp-element-caption\"><em>Customizable consent and intake forms<\/em><\/figcaption><\/figure>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n\n\n<h3 class=\"wp-block-heading\">Common billing errors to avoid<\/h3>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Using J9334 instead of J9332:<\/strong> J9334 is for the subcutaneous formulation. Route of administration must match the code. IV infusion uses J9332 only.<\/li><li><strong>Missing JW\/JZ modifier:<\/strong> CMS requires one of these on every single-dose vial drug claim. Omitting both creates a claim edit that results in rejection.<\/li><li><strong>Incorrect units:<\/strong> Dividing by 1 mg instead of 2 mg doubles the reported units. Always verify the per-unit denominator before submitting.<\/li><li><strong>Unsupported ICD-10 pairing:<\/strong> Submitting a diagnosis code outside G70.00\/G70.01 (or payer-approved equivalents) without documented medical necessity typically results in a medical necessity denial.<\/li><li><strong>No prior authorization:<\/strong> Commercial and Medicare Advantage plans usually require PA. Submitting without a valid authorization number on file results in denial, often non-reversible without appeal.<\/li><\/ul>\n\n\n        <div id=\"book_a_demo\">\n            <div class=\"left-side\">\n                <div class=\"logo\">\n                    <img decoding=\"async\"\n                        src=\"https:\/\/pabau.com\/wp-content\/uploads\/2026\/01\/Logo.svg\"\n                        alt=\"Logo\"\n                        loading=\"lazy\"\n                    \/>\n                <\/div>\n\n                <h3 class=\"heading\">\n                    Manage HCPCS billing with less manual work                <\/h3>\n\n                <p class=\"description\">\n                    Pabau&#8217;s claims management software helps infusion and specialty practices track J-code billing, apply modifiers correctly, and reconcile Medicare fee schedule changes quarterly.                <\/p>\n\n                <div class=\"button-group\">\n                    <a href=\"\/book-demo\/\" class=\"btn btn-scale-effect btn-cta-color btn-md\">\n                        <span class=\"btn-text\">Book a demo<\/span>\n                        <div class=\"btn-icon btn-icon-right\" aria-hidden=\"true\">\n                            <svg\n                                width=\"14\"\n                                height=\"12\"\n                                viewBox=\"0 0 14 12\"\n                                fill=\"none\"\n                                xmlns=\"http:\/\/www.w3.org\/2000\/svg\"\n                            >\n                                <path\n                                    d=\"M0.75 4.77295C0.335786 4.77295 0 5.10874 0 5.52295C0 5.93716 0.335786 6.27295 0.75 6.27295V5.52295V4.77295ZM13.2803 6.05328C13.5732 5.76039 13.5732 5.28551 13.2803 4.99262L8.50736 0.219648C8.21447 -0.073245 7.73959 -0.073245 7.4467 0.219648C7.15381 0.512542 7.15381 0.987415 7.4467 1.28031L11.6893 5.52295L7.4467 9.76559C7.15381 10.0585 7.15381 10.5334 7.4467 10.8263C7.73959 11.1191 8.21447 11.1191 8.50736 10.8263L13.2803 6.05328ZM0.75 5.52295V6.27295L12.75 6.27295V5.52295V4.77295L0.75 4.77295V5.52295Z\"\n                                    fill=\"currentColor\"\n                                ><\/path>\n                            <\/svg>\n                        <\/div>\n                    <\/a>\n                <\/div>\n            <\/div>\n\n            <div class=\"right-side\">\n                <img decoding=\"async\"\n                    src=\"https:\/\/pabau.com\/wp-content\/uploads\/2026\/01\/Home-Page-Concept-4.webp\"\n                    alt=\"Pabau claims management dashboard\"\n                    loading=\"lazy\"\n                \/>\n            <\/div>\n        <\/div>\n        \n\n\n<h2 class=\"wp-block-heading\">Related HCPCS codes<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Billers working with efgartigimod products or similar neurology biologics should be familiar with the related codes below. The J9332\/J9334 distinction is the most critical, but other chemotherapy J-codes in the J9000-J9999 range follow similar billing logic. Billing teams handling other neurology infusion biologics may also reference J2323, which follows a similar reimbursement structure.<\/p>\n\n\n\n<table style=\"width:100%;border-collapse:separate;border-spacing:0;border-radius:12px;overflow:hidden;font-size:15px;line-height:1.5;margin:1.5em 0 2em;box-shadow:0 2px 12px rgba(0,0,0,0.08)\">\n<thead>\n<tr>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">Code<\/th>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">Description<\/th>\n<th style=\"background:#121D36;color:#fff;padding:14px 16px;text-align:left;font-weight:600;font-size:14px;letter-spacing:0.3px;border-bottom:2px solid #2BADD4\">Key Difference from J9332<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"border-bottom:1px solid #E8ECF0\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">J9332<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Injection, efgartigimod alfa-fcab, 2 mg (Vyvgart IV)<\/td>\n<td style=\"padding:12px 16px;color:#374151\">This code. IV infusion only.<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0;background:#F9FAFB\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">J9334<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Injection, efgartigimod alfa and hyaluronidase-qvfc, 2 mg (Vyvgart Hytrulo)<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Subcutaneous formulation. Different drug product. Cannot substitute for J9332.<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">96365<\/td>\n<td style=\"padding:12px 16px;color:#374151\">IV infusion, initial (CPT)<\/td>\n<td style=\"padding:12px 16px;color:#374151\">CPT code for the administration service billed alongside J9332 in the physician office setting<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #E8ECF0;background:#F9FAFB\">\n<td style=\"padding:12px 16px;font-weight:600;color:#121D36\">96366<\/td>\n<td style=\"padding:12px 16px;color:#374151\">IV infusion, each additional hour (CPT)<\/td>\n<td style=\"padding:12px 16px;color:#374151\">Added if infusion extends beyond the initial hour; billed with 96365<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n<p class=\"wp-block-paragraph\">For reference, you can search the full HCPCS Level II code range using the <a href=\"https:\/\/www.pgmbilling.com\/hcpcs-lookup-tool\/\" target=\"_blank\" rel=\"nofollow noopener\">PGM Billing HCPCS lookup tool<\/a> or the <a href=\"https:\/\/clinicaltables.nlm.nih.gov\/apidoc\/hcpcs\/v3\/doc.html\" target=\"_blank\" rel=\"nofollow noopener\">NLM Clinical Table Search API<\/a> for programmatic lookups in billing systems.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Practices building out their injectable drug procedure codes reference library will find both resources useful for bulk code verification.<\/p>\n\n\n        <div id=\"pro_tip\">\n            <div class=\"img\">\n                <svg width=\"42\" height=\"42\" viewBox=\"0 0 42 42\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path fill-rule=\"evenodd\" clip-rule=\"evenodd\"\n                        d=\"M12.6383 19.5238C12.6632 21.2071 12.8734 22.9926 12.0685 24.5523C11.0341 26.8917 8.45076 28.169 7.56292 30.5918C6.63082 33.1061 7.19505 36.185 9.31371 37.9786C10.929 39.5678 13.4183 39.9873 15.6061 39.5463C17.4592 39.073 19.1049 37.8388 19.9706 36.1608C20.781 34.7141 20.7866 32.9904 20.5293 31.3985C20.1006 29.3092 18.3775 27.8705 16.9807 26.362C14.8814 24.1005 14.6684 20.6854 15.595 17.8915C16.4331 15.4768 19.0026 14.2344 20.0425 11.9461C20.7202 10.6769 20.7506 9.20327 20.6068 7.81304C20.1864 5.40098 18.3139 3.23631 15.8716 2.56674C13.9742 2.03969 11.8224 2.30052 10.1739 3.37614C8.70522 4.34688 7.5878 5.86618 7.28356 7.58178C6.76081 9.82981 7.53525 12.2822 9.20307 13.9118C10.7658 15.4741 12.4806 17.2273 12.6383 19.5238Z\"\n                        fill=\"#2BADD4\" \/>\n                    <path fill-rule=\"evenodd\" clip-rule=\"evenodd\"\n                        d=\"M22.7048 19.8387C22.6822 22.3279 24.4507 24.6234 26.7493 25.4682C28.0531 25.961 29.4725 25.9183 30.7989 25.5487C32.0575 24.9955 33.301 24.2237 34.0069 23.0092C34.8384 21.5811 35.2982 19.8286 34.7832 18.2094C34.3611 16.2507 32.8739 14.6541 31.0275 13.9426C28.6736 12.9595 25.8073 13.7942 24.1719 15.7001C23.2022 16.8366 22.6143 18.3326 22.7048 19.8387Z\"\n                        fill=\"#2BADD4\" \/>\n                <\/svg>\n            <\/div>\n            <div class=\"text\">\n                <h3>Pro Tip<\/h3>\n                <p>Run a quarterly reconciliation against the CMS ASP Drug Pricing File every time new quarterly rates are published (typically six weeks before the quarter start). Flag any J9332 claims already submitted where the fee schedule has shifted by more than 5%. These are candidates for corrected claims or adjustments depending on your payer contracts.<\/p>\n            <\/div>\n        <\/div>\n    \n\n\n<h2 class=\"wp-block-heading\">Streamlining J9332 billing workflows<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Infusion practices billing J9332, including those running specialized IV therapy EMR software, regularly run into the same friction points: quarterly ASP reconciliation, JW modifier documentation, and prior authorization tracking across multiple payers. Each requires consistent protocols rather than ad hoc processes.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Practices that integrate their practice management software with their billing workflows can automate several of these touchpoints. Automated fee schedule syncing, modifier rule sets by payer, and structured prior authorization checklists reduce claim error rates without requiring billing staff to manually track every policy update.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For practices billing other specialty biologics.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Related HCPCS codes<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/pabau.com\/procedure-codes\/hcpcs-code-j7030-normal-saline-infusion\/\">HCPCS code J7030 \u2014 Normal Saline Infusion<\/a><\/li>\n\n\n<li><a href=\"https:\/\/pabau.com\/procedure-codes\/hcpcs-code-j9334-efgartigimod-alfa-injection\/\">HCPCS code J9334 \u2014 Efgartigimod Alfa and Hyaluronidase-qvfc (Vyvgart Hytrulo) Injection<\/a><\/li>\n\n\n<li><a href=\"https:\/\/pabau.com\/procedure-codes\/hcpcs-code-j9999\/\">HCPCS code J9999 Antineoplastic Drugs<\/a><\/li>\n\n\n<li><a href=\"https:\/\/pabau.com\/procedure-codes\/hcpcs-code-j2469\/\">HCPCS Code J2469 \u2014 palonosetron<\/a><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Conclusion<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">HCPCS Code J9332 is a high-stakes code. The drug cost per cycle is significant, and payer scrutiny on biologic claims is high. The distinction between J9332 (IV) and J9334 (subcutaneous) catches billing teams off guard more often than it should.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Accurate billing comes down to three things:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>The right code for the right formulation<\/li><li>The correct unit calculation per 2 mg administered<\/li><li>The JW or JZ modifier on every claim<\/li><\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Pabau&#8217;s claims management software helps specialty and infusion practices. To see how it works in practice, <a href=\"https:\/\/pabau.com\/book-demo\/\">book a demo<\/a> with the team.<\/p>\n\n\n        <div id=\"expert_picks\">\n            <div class=\"header\">\n                                    <img decoding=\"async\" src=\"https:\/\/pabau.com\/wp-content\/uploads\/2025\/11\/Expert-Picks.svg\" alt=\"Continue your research\" height=\"42\" width=\"42\">\n                                <h3>Continue your research<\/h3>\n            <\/div>\n            <div class=\"content\">\n                                                            <div class=\"item\">\n                            <div>\n                                <svg width=\"20\" height=\"27\" viewBox=\"0 0 20 27\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                                    <path\n                                        d=\"M18.6223 14.3857C19.1246 13.8975 19.1246 13.1045 18.6223 12.6162L12.1938 6.36621C11.6915 5.87793 10.8759 5.87793 10.3737 6.36621C9.87143 6.85449 9.87143 7.64746 10.3737 8.13574L14.6125 12.2529H2.28571C1.57455 12.2529 1 12.8115 1 13.5029C1 14.1943 1.57455 14.7529 2.28571 14.7529H14.6085L10.3777 18.8701C9.87545 19.3584 9.87545 20.1514 10.3777 20.6396C10.8799 21.1279 11.6955 21.1279 12.1978 20.6396L18.6263 14.3896L18.6223 14.3857Z\"\n                                        fill=\"#54B2D3\" \/>\n                                <\/svg>\n                            <\/div>\n                            <p><strong>Billing a related neurology infusion biologic?<\/strong> <a href=\"https:\/\/pabau.com\/procedure-codes\/hcpcs-code-j2323\/\">J2323<\/a> covers Natalizumab infusions, reimbursed under the same ASP-based methodology and JW\/JZ modifier rules as J9332.<\/p>\n                        <\/div>\n                                                                                <div class=\"item\">\n                            <div>\n                                <svg width=\"20\" height=\"27\" viewBox=\"0 0 20 27\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                                    <path\n                                        d=\"M18.6223 14.3857C19.1246 13.8975 19.1246 13.1045 18.6223 12.6162L12.1938 6.36621C11.6915 5.87793 10.8759 5.87793 10.3737 6.36621C9.87143 6.85449 9.87143 7.64746 10.3737 8.13574L14.6125 12.2529H2.28571C1.57455 12.2529 1 12.8115 1 13.5029C1 14.1943 1.57455 14.7529 2.28571 14.7529H14.6085L10.3777 18.8701C9.87545 19.3584 9.87545 20.1514 10.3777 20.6396C10.8799 21.1279 11.6955 21.1279 12.1978 20.6396L18.6263 14.3896L18.6223 14.3857Z\"\n                                        fill=\"#54B2D3\" \/>\n                                <\/svg>\n                            <\/div>\n                            <p><strong>Administering other J-code injectables?<\/strong> <a href=\"https:\/\/pabau.com\/procedure-codes\/hcpcs-code-j3300\/\">J3300<\/a> walks through billing a common preservative-free steroid injection.<\/p>\n                        <\/div>\n                                                                                <div class=\"item\">\n                            <div>\n                                <svg width=\"20\" height=\"27\" viewBox=\"0 0 20 27\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                                    <path\n                                        d=\"M18.6223 14.3857C19.1246 13.8975 19.1246 13.1045 18.6223 12.6162L12.1938 6.36621C11.6915 5.87793 10.8759 5.87793 10.3737 6.36621C9.87143 6.85449 9.87143 7.64746 10.3737 8.13574L14.6125 12.2529H2.28571C1.57455 12.2529 1 12.8115 1 13.5029C1 14.1943 1.57455 14.7529 2.28571 14.7529H14.6085L10.3777 18.8701C9.87545 19.3584 9.87545 20.1514 10.3777 20.6396C10.8799 21.1279 11.6955 21.1279 12.1978 20.6396L18.6263 14.3896L18.6223 14.3857Z\"\n                                        fill=\"#54B2D3\" \/>\n                                <\/svg>\n                            <\/div>\n                            <p><strong>Billing another biosimilar infusion drug?<\/strong> <a href=\"https:\/\/pabau.com\/procedure-codes\/hcpcs-code-q5114\/\">Q5114<\/a> covers billing Trastuzumab-dkst (Ogivri), reimbursed the same way as other Part B specialty biologics.<\/p>\n                        <\/div>\n                                                <\/div>\n        <\/div>\n    \n\n\n<h2 class=\"wp-block-heading\">Frequently Asked Questions<\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1784200216745\"><h3 class=\"schema-faq-question\">What is HCPCS Code J9332 used for?<\/h3> <p class=\"schema-faq-answer\">HCPCS Code J9332 is used to report injection of efgartigimod alfa-fcab, 2 mg (Vyvgart), an intravenous biologic treatment for generalized myasthenia gravis (gMG) in adult patients. Following the FDA&#8217;s May 2026 label expansion, Vyvgart is approved across all gMG antibody serotypes, including AChR-positive, MuSK-positive, LRP4-positive, and seronegative patients. It is classified under the HCPCS J9000-J9999 chemotherapy drug range and reimbursed under Medicare Part B.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1784200216746\"><h3 class=\"schema-faq-question\">What is the difference between J9332 and J9334?<\/h3> <p class=\"schema-faq-answer\">J9332 covers the intravenous formulation of efgartigimod alfa-fcab (Vyvgart IV), while J9334 covers the subcutaneous formulation (Vyvgart Hytrulo, efgartigimod alfa and hyaluronidase-qvfc). These are separate drug products with different routes of administration and distinct HCPCS codes. Submitting J9332 for a subcutaneous infusion is a billing error that will typically result in a denial.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1784200216747\"><h3 class=\"schema-faq-question\">How is J9332 billed per unit?<\/h3> <p class=\"schema-faq-answer\">J9332 is billed per 2 mg of efgartigimod alfa-fcab administered. To calculate units, divide the total milligrams administered by 2. A 700 mg dose equals 350 units. Any wasted drug from a single-dose vial is reported on a separate claim line using modifier JW.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1784200216748\"><h3 class=\"schema-faq-question\">What ICD-10 codes are used with J9332?<\/h3> <p class=\"schema-faq-answer\">The two primary ICD-10 codes used with J9332 are G70.01 (myasthenia gravis with acute exacerbation) and G70.00 (myasthenia gravis without acute exacerbation). G70.01 applies when the patient presents with active symptoms at time of infusion; G70.00 applies during maintenance therapy cycles. Verify coverage against the applicable MAC&#8217;s LCD and individual payer policies before submitting.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1784200216749\"><h3 class=\"schema-faq-question\">What modifiers apply to HCPCS Code J9332?<\/h3> <p class=\"schema-faq-answer\">Modifier JW applies when a portion of the Vyvgart vial was discarded and not administered to the patient. Modifier JZ applies when the full vial content was administered with zero waste. CMS made JZ reporting optional on single-dose vial drug claims starting January 1, 2023, then mandatory from July 1, 2023, and MACs began editing and rejecting claims missing the JW or JZ modifier from October 1, 2023. Report the administered units on the primary claim line and discarded units on a separate JW line.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1784200216750\"><h3 class=\"schema-faq-question\">How is Vyvgart reimbursed under Medicare Part B?<\/h3> <p class=\"schema-faq-answer\">Medicare Part B reimburses Vyvgart (J9332) at ASP (Average Sales Price) plus 6%. CMS updates ASP-based payment rates quarterly via the ASP Drug Pricing File. Rates differ between the physician office setting (billed on a CMS-1500 under MPFS) and the hospital outpatient department (billed on a UB-04 under OPPS). Always confirm the current quarterly rate before billing.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1784200216751\"><h3 class=\"schema-faq-question\">Does J9332 require prior authorization?<\/h3> <p class=\"schema-faq-answer\">Medicare fee-for-service generally does not require prior authorization for separately payable Part B drugs, but Medicare Advantage plans and commercial payers typically do. Prior authorization for J9332 usually requires documentation of a confirmed gMG diagnosis, specialist ordering, and evidence of prior treatment trials \u2014 a positive AChR antibody test is no longer required, since Vyvgart&#8217;s approval now covers all gMG antibody serotypes. Requirements vary by payer and plan year, so verify with each payer before initiating treatment.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1784200216752\"><h3 class=\"schema-faq-question\">Where can I look up the current Medicare fee schedule for J9332?<\/h3> <p class=\"schema-faq-answer\">The current ASP-based payment rate for J9332 is published in CMS&#8217;s quarterly ASP Drug Pricing File, available on the CMS website. You can also search the fee schedule using the CMS Physician Fee Schedule lookup tool at cms.gov. Rates update every January, April, July, and October, so quarterly verification is necessary for accurate billing.<\/p> <\/div> <\/div>\n\n","protected":false},"excerpt":{"rendered":"<p>HCPCS Code J9332 reports injection of efgartigimod alfa-fcab, 2 mg (brand name Vyvgart), administered intravenously. It applies exclusively to the IV formulation. The subcutaneous version, Vyvgart Hytrulo, carries a separate code, J9334, and conflating the two creates claim denials that are slow to correct. This guide covers the code description, Medicare fee schedule methodology, applicable [&hellip;]<\/p>\n","protected":false},"author":77,"featured_media":157444,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_yoast_wpseo_linkdex":"86","_yoast_wpseo_content_score":"30","_yoast_wpseo_is_cornerstone":"","_yoast_wpseo_keywordsynonyms":"[\"\",\"\",\"\",\"\",\"\",\"\"]","_yoast_wpseo_focuskw_text_input":"","_seo_original_html":"","footnotes":""},"categories":[1433,1548],"tags":[1582,3476,1625,1636,1638,2959],"class_list":["post-157445","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-billing-codes","category-hcpcs","tag-hcpcs","tag-infusion-billing","tag-j-codes","tag-jw-modifier","tag-jz-modifier","tag-medicare-part-b-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.2 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>HCPCS Code J9332: Injection, efgartigimod alfa-fcab, 2 mg<\/title>\n<meta name=\"description\" content=\"HCPCS Code J9332 covers Vyvgart IV infusion billing: ASP+6% Medicare Part B rates, JW\/JZ modifiers, and G70 ICD-10 pairings.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HCPCS Code J9332: Injection, efgartigimod alfa-fcab, 2 mg\" \/>\n<meta property=\"og:description\" content=\"HCPCS Code J9332 covers Vyvgart IV infusion billing: ASP+6% Medicare Part B rates, JW\/JZ modifiers, and G70 ICD-10 pairings.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/\" \/>\n<meta property=\"og:site_name\" content=\"Pabau\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/Pabau\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-16T12:24:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-17T12:03:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pabau.com\/wp-content\/uploads\/2026\/07\/hcpcs-code-j9332.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Katy Piper\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@pabaucrm\" \/>\n<meta name=\"twitter:site\" content=\"@pabaucrm\" \/>\n<meta name=\"twitter:label1\" content=\"Geschreven door\" \/>\n\t<meta name=\"twitter:data1\" content=\"Katy Piper\" \/>\n\t<meta name=\"twitter:label2\" content=\"Geschatte leestijd\" \/>\n\t<meta name=\"twitter:data2\" content=\"12 minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pabau.com\\\/nl\\\/procedure-codes\\\/hcpcs-code-j9332\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pabau.com\\\/nl\\\/procedure-codes\\\/hcpcs-code-j9332\\\/\"},\"author\":{\"name\":\"Katy Piper\",\"@id\":\"https:\\\/\\\/pabau.com\\\/nl\\\/#\\\/schema\\\/person\\\/5de22f4ff3ec59b1925ef02dce956d7d\"},\"headline\":\"HCPCS Code J9332: Injection, efgartigimod alfa-fcab, 2 mg\",\"datePublished\":\"2026-07-16T12:24:59+00:00\",\"dateModified\":\"2026-08-17T12:03:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pabau.com\\\/nl\\\/procedure-codes\\\/hcpcs-code-j9332\\\/\"},\"wordCount\":2496,\"publisher\":{\"@id\":\"https:\\\/\\\/pabau.com\\\/nl\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pabau.com\\\/nl\\\/procedure-codes\\\/hcpcs-code-j9332\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/pabau.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/hcpcs-code-j9332.webp\",\"keywords\":[\"Hcpcs\",\"Infusion Billing\",\"J Codes\",\"Jw Modifier\",\"Jz Modifier\",\"Medicare Part B Drugs\"],\"articleSection\":[\"Billing Codes\",\"HCPCS\"],\"inLanguage\":\"nl-NL\"},{\"@type\":[\"WebPage\",\"FAQPage\"],\"@id\":\"https:\\\/\\\/pabau.com\\\/nl\\\/procedure-codes\\\/hcpcs-code-j9332\\\/\",\"url\":\"https:\\\/\\\/pabau.com\\\/nl\\\/procedure-codes\\\/hcpcs-code-j9332\\\/\",\"name\":\"HCPCS Code J9332: Injection, efgartigimod alfa-fcab, 2 mg\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pabau.com\\\/nl\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pabau.com\\\/nl\\\/procedure-codes\\\/hcpcs-code-j9332\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pabau.com\\\/nl\\\/procedure-codes\\\/hcpcs-code-j9332\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/pabau.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/hcpcs-code-j9332.webp\",\"datePublished\":\"2026-07-16T12:24:59+00:00\",\"dateModified\":\"2026-08-17T12:03:38+00:00\",\"description\":\"HCPCS Code J9332 covers Vyvgart IV infusion billing: ASP+6% Medicare Part B rates, JW\\\/JZ modifiers, and G70 ICD-10 pairings.\",\"mainEntity\":[{\"@id\":\"https:\\\/\\\/pabau.com\\\/nl\\\/procedure-codes\\\/hcpcs-code-j9332\\\/#faq-question-1784200216745\"},{\"@id\":\"https:\\\/\\\/pabau.com\\\/nl\\\/procedure-codes\\\/hcpcs-code-j9332\\\/#faq-question-1784200216746\"},{\"@id\":\"https:\\\/\\\/pabau.com\\\/nl\\\/procedure-codes\\\/hcpcs-code-j9332\\\/#faq-question-1784200216747\"},{\"@id\":\"https:\\\/\\\/pabau.com\\\/nl\\\/procedure-codes\\\/hcpcs-code-j9332\\\/#faq-question-1784200216748\"},{\"@id\":\"https:\\\/\\\/pabau.com\\\/nl\\\/procedure-codes\\\/hcpcs-code-j9332\\\/#faq-question-1784200216749\"},{\"@id\":\"https:\\\/\\\/pabau.com\\\/nl\\\/procedure-codes\\\/hcpcs-code-j9332\\\/#faq-question-1784200216750\"},{\"@id\":\"https:\\\/\\\/pabau.com\\\/nl\\\/procedure-codes\\\/hcpcs-code-j9332\\\/#faq-question-1784200216751\"},{\"@id\":\"https:\\\/\\\/pabau.com\\\/nl\\\/procedure-codes\\\/hcpcs-code-j9332\\\/#faq-question-1784200216752\"}],\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pabau.com\\\/nl\\\/procedure-codes\\\/hcpcs-code-j9332\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/pabau.com\\\/nl\\\/procedure-codes\\\/hcpcs-code-j9332\\\/#primaryimage\",\"url\":\"https:\\\/\\\/pabau.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/hcpcs-code-j9332.webp\",\"contentUrl\":\"https:\\\/\\\/pabau.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/hcpcs-code-j9332.webp\",\"width\":1200,\"height\":630},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pabau.com\\\/nl\\\/#website\",\"url\":\"https:\\\/\\\/pabau.com\\\/nl\\\/\",\"name\":\"Pabau\",\"description\":\"Clinic Software for your Business | Go Paperless Today\",\"publisher\":{\"@id\":\"https:\\\/\\\/pabau.com\\\/nl\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pabau.com\\\/nl\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pabau.com\\\/nl\\\/#organization\",\"name\":\"Pabau\",\"url\":\"https:\\\/\\\/pabau.com\\\/nl\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/pabau.com\\\/nl\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/pabau.com\\\/wp-content\\\/uploads\\\/2022\\\/05\\\/Logo-4-e1654525062364.png\",\"contentUrl\":\"https:\\\/\\\/pabau.com\\\/wp-content\\\/uploads\\\/2022\\\/05\\\/Logo-4-e1654525062364.png\",\"width\":736,\"height\":195,\"caption\":\"Pabau\"},\"image\":{\"@id\":\"https:\\\/\\\/pabau.com\\\/nl\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/Pabau\\\/\",\"https:\\\/\\\/x.com\\\/pabaucrm\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/pabau-ltd\\\/\",\"https:\\\/\\\/www.instagram.com\\\/pabausoftware\\\/\"],\"description\":\"Pabau is an all-in-one healthcare practice management software platform designed for clinics, medspas, therapists, and medical professionals. It combines scheduling, electronic health records, clinical forms, payments, marketing automation, reporting, and patient engagement tools into one secure cloud system to help practices streamline operations and grow their business.\",\"foundingDate\":\"2011-10-20\",\"numberOfEmployees\":{\"@type\":\"QuantitativeValue\",\"minValue\":\"201\",\"maxValue\":\"500\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pabau.com\\\/nl\\\/#\\\/schema\\\/person\\\/5de22f4ff3ec59b1925ef02dce956d7d\",\"name\":\"Katy Piper\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/pabau.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/cropped-Snip20260306_177-96x96.png\",\"url\":\"https:\\\/\\\/pabau.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/cropped-Snip20260306_177-96x96.png\",\"contentUrl\":\"https:\\\/\\\/pabau.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/cropped-Snip20260306_177-96x96.png\",\"caption\":\"Katy Piper\"},\"description\":\"Katy Piper is a content writer covering aesthetics, dermatology, and clinic operations, with a knack for making clinical detail feel approachable. Outside of work, she's usually chasing her border collie around muddy fields or hunting down the best flat white in town.\",\"url\":\"https:\\\/\\\/pabau.com\\\/nl\\\/blog\\\/author\\\/katy-piper\\\/\"},{\"@type\":\"Question\",\"@id\":\"https:\\\/\\\/pabau.com\\\/nl\\\/procedure-codes\\\/hcpcs-code-j9332\\\/#faq-question-1784200216745\",\"position\":1,\"url\":\"https:\\\/\\\/pabau.com\\\/nl\\\/procedure-codes\\\/hcpcs-code-j9332\\\/#faq-question-1784200216745\",\"name\":\"What is HCPCS Code J9332 used for?\",\"answerCount\":1,\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"HCPCS Code J9332 is used to report injection of efgartigimod alfa-fcab, 2 mg (Vyvgart), an intravenous biologic treatment for generalized myasthenia gravis (gMG) in adult patients. Following the FDA's May 2026 label expansion, Vyvgart is approved across all gMG antibody serotypes, including AChR-positive, MuSK-positive, LRP4-positive, and seronegative patients. It is classified under the HCPCS J9000-J9999 chemotherapy drug range and reimbursed under Medicare Part B.\",\"inLanguage\":\"nl-NL\"},\"inLanguage\":\"nl-NL\"},{\"@type\":\"Question\",\"@id\":\"https:\\\/\\\/pabau.com\\\/nl\\\/procedure-codes\\\/hcpcs-code-j9332\\\/#faq-question-1784200216746\",\"position\":2,\"url\":\"https:\\\/\\\/pabau.com\\\/nl\\\/procedure-codes\\\/hcpcs-code-j9332\\\/#faq-question-1784200216746\",\"name\":\"What is the difference between J9332 and J9334?\",\"answerCount\":1,\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"J9332 covers the intravenous formulation of efgartigimod alfa-fcab (Vyvgart IV), while J9334 covers the subcutaneous formulation (Vyvgart Hytrulo, efgartigimod alfa and hyaluronidase-qvfc). These are separate drug products with different routes of administration and distinct HCPCS codes. Submitting J9332 for a subcutaneous infusion is a billing error that will typically result in a denial.\",\"inLanguage\":\"nl-NL\"},\"inLanguage\":\"nl-NL\"},{\"@type\":\"Question\",\"@id\":\"https:\\\/\\\/pabau.com\\\/nl\\\/procedure-codes\\\/hcpcs-code-j9332\\\/#faq-question-1784200216747\",\"position\":3,\"url\":\"https:\\\/\\\/pabau.com\\\/nl\\\/procedure-codes\\\/hcpcs-code-j9332\\\/#faq-question-1784200216747\",\"name\":\"How is J9332 billed per unit?\",\"answerCount\":1,\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"J9332 is billed per 2 mg of efgartigimod alfa-fcab administered. To calculate units, divide the total milligrams administered by 2. A 700 mg dose equals 350 units. Any wasted drug from a single-dose vial is reported on a separate claim line using modifier JW.\",\"inLanguage\":\"nl-NL\"},\"inLanguage\":\"nl-NL\"},{\"@type\":\"Question\",\"@id\":\"https:\\\/\\\/pabau.com\\\/nl\\\/procedure-codes\\\/hcpcs-code-j9332\\\/#faq-question-1784200216748\",\"position\":4,\"url\":\"https:\\\/\\\/pabau.com\\\/nl\\\/procedure-codes\\\/hcpcs-code-j9332\\\/#faq-question-1784200216748\",\"name\":\"What ICD-10 codes are used with J9332?\",\"answerCount\":1,\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The two primary ICD-10 codes used with J9332 are G70.01 (myasthenia gravis with acute exacerbation) and G70.00 (myasthenia gravis without acute exacerbation). G70.01 applies when the patient presents with active symptoms at time of infusion; G70.00 applies during maintenance therapy cycles. Verify coverage against the applicable MAC's LCD and individual payer policies before submitting.\",\"inLanguage\":\"nl-NL\"},\"inLanguage\":\"nl-NL\"},{\"@type\":\"Question\",\"@id\":\"https:\\\/\\\/pabau.com\\\/nl\\\/procedure-codes\\\/hcpcs-code-j9332\\\/#faq-question-1784200216749\",\"position\":5,\"url\":\"https:\\\/\\\/pabau.com\\\/nl\\\/procedure-codes\\\/hcpcs-code-j9332\\\/#faq-question-1784200216749\",\"name\":\"What modifiers apply to HCPCS Code J9332?\",\"answerCount\":1,\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Modifier JW applies when a portion of the Vyvgart vial was discarded and not administered to the patient. Modifier JZ applies when the full vial content was administered with zero waste. CMS made JZ reporting optional on single-dose vial drug claims starting January 1, 2023, then mandatory from July 1, 2023, and MACs began editing and rejecting claims missing the JW or JZ modifier from October 1, 2023. Report the administered units on the primary claim line and discarded units on a separate JW line.\",\"inLanguage\":\"nl-NL\"},\"inLanguage\":\"nl-NL\"},{\"@type\":\"Question\",\"@id\":\"https:\\\/\\\/pabau.com\\\/nl\\\/procedure-codes\\\/hcpcs-code-j9332\\\/#faq-question-1784200216750\",\"position\":6,\"url\":\"https:\\\/\\\/pabau.com\\\/nl\\\/procedure-codes\\\/hcpcs-code-j9332\\\/#faq-question-1784200216750\",\"name\":\"How is Vyvgart reimbursed under Medicare Part B?\",\"answerCount\":1,\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Medicare Part B reimburses Vyvgart (J9332) at ASP (Average Sales Price) plus 6%. CMS updates ASP-based payment rates quarterly via the ASP Drug Pricing File. Rates differ between the physician office setting (billed on a CMS-1500 under MPFS) and the hospital outpatient department (billed on a UB-04 under OPPS). Always confirm the current quarterly rate before billing.\",\"inLanguage\":\"nl-NL\"},\"inLanguage\":\"nl-NL\"},{\"@type\":\"Question\",\"@id\":\"https:\\\/\\\/pabau.com\\\/nl\\\/procedure-codes\\\/hcpcs-code-j9332\\\/#faq-question-1784200216751\",\"position\":7,\"url\":\"https:\\\/\\\/pabau.com\\\/nl\\\/procedure-codes\\\/hcpcs-code-j9332\\\/#faq-question-1784200216751\",\"name\":\"Does J9332 require prior authorization?\",\"answerCount\":1,\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Medicare fee-for-service generally does not require prior authorization for separately payable Part B drugs, but Medicare Advantage plans and commercial payers typically do. Prior authorization for J9332 usually requires documentation of a confirmed gMG diagnosis, specialist ordering, and evidence of prior treatment trials \u2014 a positive AChR antibody test is no longer required, since Vyvgart's approval now covers all gMG antibody serotypes. Requirements vary by payer and plan year, so verify with each payer before initiating treatment.\",\"inLanguage\":\"nl-NL\"},\"inLanguage\":\"nl-NL\"},{\"@type\":\"Question\",\"@id\":\"https:\\\/\\\/pabau.com\\\/nl\\\/procedure-codes\\\/hcpcs-code-j9332\\\/#faq-question-1784200216752\",\"position\":8,\"url\":\"https:\\\/\\\/pabau.com\\\/nl\\\/procedure-codes\\\/hcpcs-code-j9332\\\/#faq-question-1784200216752\",\"name\":\"Where can I look up the current Medicare fee schedule for J9332?\",\"answerCount\":1,\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The current ASP-based payment rate for J9332 is published in CMS's quarterly ASP Drug Pricing File, available on the CMS website. You can also search the fee schedule using the CMS Physician Fee Schedule lookup tool at cms.gov. Rates update every January, April, July, and October, so quarterly verification is necessary for accurate billing.\",\"inLanguage\":\"nl-NL\"},\"inLanguage\":\"nl-NL\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"HCPCS Code J9332: Injection, efgartigimod alfa-fcab, 2 mg","description":"HCPCS Code J9332 covers Vyvgart IV infusion billing: ASP+6% Medicare Part B rates, JW\/JZ modifiers, and G70 ICD-10 pairings.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/","og_locale":"nl_NL","og_type":"article","og_title":"HCPCS Code J9332: Injection, efgartigimod alfa-fcab, 2 mg","og_description":"HCPCS Code J9332 covers Vyvgart IV infusion billing: ASP+6% Medicare Part B rates, JW\/JZ modifiers, and G70 ICD-10 pairings.","og_url":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/","og_site_name":"Pabau","article_publisher":"https:\/\/www.facebook.com\/Pabau\/","article_published_time":"2026-07-16T12:24:59+00:00","article_modified_time":"2026-08-17T12:03:38+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/pabau.com\/wp-content\/uploads\/2026\/07\/hcpcs-code-j9332.webp","type":"image\/webp"}],"author":"Katy Piper","twitter_card":"summary_large_image","twitter_creator":"@pabaucrm","twitter_site":"@pabaucrm","twitter_misc":{"Geschreven door":"Katy Piper","Geschatte leestijd":"12 minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/#article","isPartOf":{"@id":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/"},"author":{"name":"Katy Piper","@id":"https:\/\/pabau.com\/nl\/#\/schema\/person\/5de22f4ff3ec59b1925ef02dce956d7d"},"headline":"HCPCS Code J9332: Injection, efgartigimod alfa-fcab, 2 mg","datePublished":"2026-07-16T12:24:59+00:00","dateModified":"2026-08-17T12:03:38+00:00","mainEntityOfPage":{"@id":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/"},"wordCount":2496,"publisher":{"@id":"https:\/\/pabau.com\/nl\/#organization"},"image":{"@id":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/#primaryimage"},"thumbnailUrl":"https:\/\/pabau.com\/wp-content\/uploads\/2026\/07\/hcpcs-code-j9332.webp","keywords":["Hcpcs","Infusion Billing","J Codes","Jw Modifier","Jz Modifier","Medicare Part B Drugs"],"articleSection":["Billing Codes","HCPCS"],"inLanguage":"nl-NL"},{"@type":["WebPage","FAQPage"],"@id":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/","url":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/","name":"HCPCS Code J9332: Injection, efgartigimod alfa-fcab, 2 mg","isPartOf":{"@id":"https:\/\/pabau.com\/nl\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/#primaryimage"},"image":{"@id":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/#primaryimage"},"thumbnailUrl":"https:\/\/pabau.com\/wp-content\/uploads\/2026\/07\/hcpcs-code-j9332.webp","datePublished":"2026-07-16T12:24:59+00:00","dateModified":"2026-08-17T12:03:38+00:00","description":"HCPCS Code J9332 covers Vyvgart IV infusion billing: ASP+6% Medicare Part B rates, JW\/JZ modifiers, and G70 ICD-10 pairings.","mainEntity":[{"@id":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/#faq-question-1784200216745"},{"@id":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/#faq-question-1784200216746"},{"@id":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/#faq-question-1784200216747"},{"@id":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/#faq-question-1784200216748"},{"@id":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/#faq-question-1784200216749"},{"@id":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/#faq-question-1784200216750"},{"@id":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/#faq-question-1784200216751"},{"@id":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/#faq-question-1784200216752"}],"inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/"]}]},{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/#primaryimage","url":"https:\/\/pabau.com\/wp-content\/uploads\/2026\/07\/hcpcs-code-j9332.webp","contentUrl":"https:\/\/pabau.com\/wp-content\/uploads\/2026\/07\/hcpcs-code-j9332.webp","width":1200,"height":630},{"@type":"WebSite","@id":"https:\/\/pabau.com\/nl\/#website","url":"https:\/\/pabau.com\/nl\/","name":"Pabau","description":"Clinic Software for your Business | Go Paperless Today","publisher":{"@id":"https:\/\/pabau.com\/nl\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pabau.com\/nl\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/pabau.com\/nl\/#organization","name":"Pabau","url":"https:\/\/pabau.com\/nl\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/pabau.com\/nl\/#\/schema\/logo\/image\/","url":"https:\/\/pabau.com\/wp-content\/uploads\/2022\/05\/Logo-4-e1654525062364.png","contentUrl":"https:\/\/pabau.com\/wp-content\/uploads\/2022\/05\/Logo-4-e1654525062364.png","width":736,"height":195,"caption":"Pabau"},"image":{"@id":"https:\/\/pabau.com\/nl\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Pabau\/","https:\/\/x.com\/pabaucrm","https:\/\/www.linkedin.com\/company\/pabau-ltd\/","https:\/\/www.instagram.com\/pabausoftware\/"],"description":"Pabau is an all-in-one healthcare practice management software platform designed for clinics, medspas, therapists, and medical professionals. It combines scheduling, electronic health records, clinical forms, payments, marketing automation, reporting, and patient engagement tools into one secure cloud system to help practices streamline operations and grow their business.","foundingDate":"2011-10-20","numberOfEmployees":{"@type":"QuantitativeValue","minValue":"201","maxValue":"500"}},{"@type":"Person","@id":"https:\/\/pabau.com\/nl\/#\/schema\/person\/5de22f4ff3ec59b1925ef02dce956d7d","name":"Katy Piper","image":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/pabau.com\/wp-content\/uploads\/2026\/03\/cropped-Snip20260306_177-96x96.png","url":"https:\/\/pabau.com\/wp-content\/uploads\/2026\/03\/cropped-Snip20260306_177-96x96.png","contentUrl":"https:\/\/pabau.com\/wp-content\/uploads\/2026\/03\/cropped-Snip20260306_177-96x96.png","caption":"Katy Piper"},"description":"Katy Piper is a content writer covering aesthetics, dermatology, and clinic operations, with a knack for making clinical detail feel approachable. Outside of work, she's usually chasing her border collie around muddy fields or hunting down the best flat white in town.","url":"https:\/\/pabau.com\/nl\/blog\/author\/katy-piper\/"},{"@type":"Question","@id":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/#faq-question-1784200216745","position":1,"url":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/#faq-question-1784200216745","name":"What is HCPCS Code J9332 used for?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"HCPCS Code J9332 is used to report injection of efgartigimod alfa-fcab, 2 mg (Vyvgart), an intravenous biologic treatment for generalized myasthenia gravis (gMG) in adult patients. Following the FDA's May 2026 label expansion, Vyvgart is approved across all gMG antibody serotypes, including AChR-positive, MuSK-positive, LRP4-positive, and seronegative patients. It is classified under the HCPCS J9000-J9999 chemotherapy drug range and reimbursed under Medicare Part B.","inLanguage":"nl-NL"},"inLanguage":"nl-NL"},{"@type":"Question","@id":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/#faq-question-1784200216746","position":2,"url":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/#faq-question-1784200216746","name":"What is the difference between J9332 and J9334?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"J9332 covers the intravenous formulation of efgartigimod alfa-fcab (Vyvgart IV), while J9334 covers the subcutaneous formulation (Vyvgart Hytrulo, efgartigimod alfa and hyaluronidase-qvfc). These are separate drug products with different routes of administration and distinct HCPCS codes. Submitting J9332 for a subcutaneous infusion is a billing error that will typically result in a denial.","inLanguage":"nl-NL"},"inLanguage":"nl-NL"},{"@type":"Question","@id":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/#faq-question-1784200216747","position":3,"url":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/#faq-question-1784200216747","name":"How is J9332 billed per unit?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"J9332 is billed per 2 mg of efgartigimod alfa-fcab administered. To calculate units, divide the total milligrams administered by 2. A 700 mg dose equals 350 units. Any wasted drug from a single-dose vial is reported on a separate claim line using modifier JW.","inLanguage":"nl-NL"},"inLanguage":"nl-NL"},{"@type":"Question","@id":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/#faq-question-1784200216748","position":4,"url":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/#faq-question-1784200216748","name":"What ICD-10 codes are used with J9332?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The two primary ICD-10 codes used with J9332 are G70.01 (myasthenia gravis with acute exacerbation) and G70.00 (myasthenia gravis without acute exacerbation). G70.01 applies when the patient presents with active symptoms at time of infusion; G70.00 applies during maintenance therapy cycles. Verify coverage against the applicable MAC's LCD and individual payer policies before submitting.","inLanguage":"nl-NL"},"inLanguage":"nl-NL"},{"@type":"Question","@id":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/#faq-question-1784200216749","position":5,"url":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/#faq-question-1784200216749","name":"What modifiers apply to HCPCS Code J9332?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Modifier JW applies when a portion of the Vyvgart vial was discarded and not administered to the patient. Modifier JZ applies when the full vial content was administered with zero waste. CMS made JZ reporting optional on single-dose vial drug claims starting January 1, 2023, then mandatory from July 1, 2023, and MACs began editing and rejecting claims missing the JW or JZ modifier from October 1, 2023. Report the administered units on the primary claim line and discarded units on a separate JW line.","inLanguage":"nl-NL"},"inLanguage":"nl-NL"},{"@type":"Question","@id":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/#faq-question-1784200216750","position":6,"url":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/#faq-question-1784200216750","name":"How is Vyvgart reimbursed under Medicare Part B?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Medicare Part B reimburses Vyvgart (J9332) at ASP (Average Sales Price) plus 6%. CMS updates ASP-based payment rates quarterly via the ASP Drug Pricing File. Rates differ between the physician office setting (billed on a CMS-1500 under MPFS) and the hospital outpatient department (billed on a UB-04 under OPPS). Always confirm the current quarterly rate before billing.","inLanguage":"nl-NL"},"inLanguage":"nl-NL"},{"@type":"Question","@id":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/#faq-question-1784200216751","position":7,"url":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/#faq-question-1784200216751","name":"Does J9332 require prior authorization?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Medicare fee-for-service generally does not require prior authorization for separately payable Part B drugs, but Medicare Advantage plans and commercial payers typically do. Prior authorization for J9332 usually requires documentation of a confirmed gMG diagnosis, specialist ordering, and evidence of prior treatment trials \u2014 a positive AChR antibody test is no longer required, since Vyvgart's approval now covers all gMG antibody serotypes. Requirements vary by payer and plan year, so verify with each payer before initiating treatment.","inLanguage":"nl-NL"},"inLanguage":"nl-NL"},{"@type":"Question","@id":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/#faq-question-1784200216752","position":8,"url":"https:\/\/pabau.com\/nl\/procedure-codes\/hcpcs-code-j9332\/#faq-question-1784200216752","name":"Where can I look up the current Medicare fee schedule for J9332?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The current ASP-based payment rate for J9332 is published in CMS's quarterly ASP Drug Pricing File, available on the CMS website. You can also search the fee schedule using the CMS Physician Fee Schedule lookup tool at cms.gov. Rates update every January, April, July, and October, so quarterly verification is necessary for accurate billing.","inLanguage":"nl-NL"},"inLanguage":"nl-NL"}]}},"yoast":{"focus_keyword":"HCPCS Code J9332","seo_title":"HCPCS Code J9332: Injection, efgartigimod alfa-fcab, 2 mg","meta_description":"HCPCS Code J9332 covers Vyvgart IV infusion billing: ASP+6% Medicare Part B rates, JW\/JZ modifiers, and G70 ICD-10 pairings.","content_score":"30","is_cornerstone":"","related_keyphrases":[{"keyword":"efgartigimod alfa injection","score":72},{"keyword":"J9332 medicare reimbursement","score":61},{"keyword":"J9332 icd-10 crosswalk","score":61},{"keyword":"J9332 modifier jw jz","score":72},{"keyword":"vyvgart billing code","score":72}]},"_links":{"self":[{"href":"https:\/\/pabau.com\/nl\/wp-json\/wp\/v2\/posts\/157445","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pabau.com\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pabau.com\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pabau.com\/nl\/wp-json\/wp\/v2\/users\/77"}],"replies":[{"embeddable":true,"href":"https:\/\/pabau.com\/nl\/wp-json\/wp\/v2\/comments?post=157445"}],"version-history":[{"count":3,"href":"https:\/\/pabau.com\/nl\/wp-json\/wp\/v2\/posts\/157445\/revisions"}],"predecessor-version":[{"id":182655,"href":"https:\/\/pabau.com\/nl\/wp-json\/wp\/v2\/posts\/157445\/revisions\/182655"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pabau.com\/nl\/wp-json\/wp\/v2\/media\/157444"}],"wp:attachment":[{"href":"https:\/\/pabau.com\/nl\/wp-json\/wp\/v2\/media?parent=157445"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pabau.com\/nl\/wp-json\/wp\/v2\/categories?post=157445"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pabau.com\/nl\/wp-json\/wp\/v2\/tags?post=157445"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}